Shares of Small Pharma Inc. (CVE:DMT – Get Free Report) were down 6.3% on Friday . The stock traded as low as C$0.15 and last traded at C$0.15. Approximately 1,890,765 shares were traded during trading, an increase of 538% from the average daily volume of 296,159 shares. The stock had previously closed at C$0.16.
Small Pharma Stock Down 6.3 %
The company has a market capitalization of C$50.37 million, a price-to-earnings ratio of -2.14 and a beta of 0.86. The stock’s fifty day simple moving average is C$0.15 and its two-hundred day simple moving average is C$0.15. The company has a debt-to-equity ratio of 5.95, a current ratio of 2.63 and a quick ratio of 6.28.
Small Pharma Company Profile
Small Pharma Inc, a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Its clinical program is based on N,N, dimethyltryptamine, a naturally occurring psychoactive molecule. The company's product includes SPL026, which is in clinical Phase IIa for the treatment of major depressive disorder; and SPL028, an injectable formulation of deuterated DMT, which is in Phase 1 clinical trial, as well as SPL801B, an oral dosage.
Read More
- Five stocks we like better than Small Pharma
- The How And Why of Investing in Oil Stocks
- Symbotic Shares Down 37%—Is It Time for Bravery or Caution?
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- High-Yield Healthcare: 3 Stocks With Strong Dividends
- What Are Dividends? Buy the Best Dividend Stocks
- Beyond the Bargain Bin: 3 Stocks Leading Discount Retail
Receive News & Ratings for Small Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Small Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
